Compare Stocks: BNTC, DMRA, REPL, and ORIC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTC Benitec Biopharma	$8.46 +2.1%	$11.45	$8.25 ▼ $16.76	$295.11M	0.25	143,991 shs	153,730 shs
DMRA Damora Therapeutics, Inc. Common Stock	$18.74 +1.7%	$25.90	$4.95 ▼ $38.33	$1.16B	1.43	429,168 shs	357,623 shs
ORIC Oric Pharmaceuticals	$12.77 +10.2%	$12.98	$7.23 ▼ $14.68	$1.32B	0.99	1.69 million shs	1.56 million shs
REPL Replimune Group	$11.75 +3.2%	$13.88	$1.50 ▼ $16.33	$1.10B	0.93	4.41 million shs	1.61 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTC Benitec Biopharma	-3.94%	-7.79%	-31.37%	-34.52%	-44.95%
DMRA Damora Therapeutics, Inc. Common Stock	-0.70%	-8.94%	-35.08%	-39.05%	+62.38%
ORIC Oric Pharmaceuticals	+2.48%	-3.50%	-8.38%	+8.01%	-11.93%
REPL Replimune Group	-5.95%	-13.71%	-13.12%	+19.64%	+161.84%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTC Benitec Biopharma	$8.46 +2.1%	$11.45	$8.25 ▼ $16.76	$295.11M	0.25	143,991 shs	153,730 shs
DMRA Damora Therapeutics, Inc. Common Stock	$18.74 +1.7%	$25.90	$4.95 ▼ $38.33	$1.16B	1.43	429,168 shs	357,623 shs
ORIC Oric Pharmaceuticals	$12.77 +10.2%	$12.98	$7.23 ▼ $14.68	$1.32B	0.99	1.69 million shs	1.56 million shs
REPL Replimune Group	$11.75 +3.2%	$13.88	$1.50 ▼ $16.33	$1.10B	0.93	4.41 million shs	1.61 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTC Benitec Biopharma	-3.94%	-7.79%	-31.37%	-34.52%	-44.95%
DMRA Damora Therapeutics, Inc. Common Stock	-0.70%	-8.94%	-35.08%	-39.05%	+62.38%
ORIC Oric Pharmaceuticals	+2.48%	-3.50%	-8.38%	+8.01%	-11.93%
REPL Replimune Group	-5.95%	-13.71%	-13.12%	+19.64%	+161.84%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTC Benitec Biopharma	2.60	Moderate Buy	$24.00	183.69% Upside
DMRA Damora Therapeutics, Inc. Common Stock	3.00	Buy	$46.50	148.13% Upside
ORIC Oric Pharmaceuticals	2.81	Moderate Buy	$21.17	65.75% Upside
REPL Replimune Group	2.60	Moderate Buy	$12.00	2.13% Upside

Current Analyst Ratings Breakdown

Latest BNTC, DMRA, REPL, and ORIC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/14/2026	ORIC Oric Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$23.00 ➝ $26.00
10/6/2026	BNTC Benitec Biopharma	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
10/5/2026	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
10/5/2026	ORIC Oric Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$26.00
9/29/2026	DMRA Damora Therapeutics, Inc. Common Stock	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$40.00
9/28/2026	BNTC Benitec Biopharma	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/25/2026	DMRA Damora Therapeutics, Inc. Common Stock	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$40.00 ➝ $60.00
9/23/2026	ORIC Oric Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$26.00
9/15/2026	BNTC Benitec Biopharma	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
9/15/2026	BNTC Benitec Biopharma	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Outperform
9/15/2026	BNTC Benitec Biopharma	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$16.00 ➝ $17.00

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	$5.15 per share	N/A
DMRA Damora Therapeutics, Inc. Common Stock	N/A	N/A	N/A	N/A	($110.11) per share	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.90 per share	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	$2.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTC Benitec Biopharma	-$45.55M	-$0.98	N/A	N/A	N/A	N/A	-28.41%	-27.76%	11/13/2026 (Estimated)
DMRA Damora Therapeutics, Inc. Common Stock	-$209.84M	-$3.37	N/A	N/A	N/A	N/A	-176.39%	-77.86%	N/A
ORIC Oric Pharmaceuticals	-$129.47M	-$1.35	N/A	N/A	N/A	N/A	-35.35%	-33.39%	11/12/2026 (Estimated)
REPL Replimune Group	-$313.94M	-$3.15	N/A	N/A	N/A	N/A	-159.32%	-90.84%	11/5/2026 (Estimated)

Latest BNTC, DMRA, REPL, and ORIC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	ORIC Oric Pharmaceuticals	-$0.3838	N/A	N/A	N/A	N/A	N/A
11/5/2026	Q2 2027	REPL Replimune Group	-$0.7840	N/A	N/A	N/A	$1.00 million	N/A
9/14/2026	Q4 2026	BNTC Benitec Biopharma	-$0.2643	-$0.26	+$0.0043	-$0.2590	$13.70 million	N/A
8/14/2026	Q1 2027	REPL Replimune Group	-$0.6940	-$0.72	-$0.0260	-$0.72	$13.60 million	N/A
8/10/2026	Q2 2026	DMRA Damora Therapeutics, Inc. Common Stock	-$0.4470	-$0.39	+$0.0570	-$0.39	N/A	N/A
8/3/2026	Q2 2026	ORIC Oric Pharmaceuticals	-$0.3594	-$0.38	-$0.0207	-$0.38	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
DMRA Damora Therapeutics, Inc. Common Stock	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTC Benitec Biopharma	N/A	34.00	34.00
DMRA Damora Therapeutics, Inc. Common Stock	N/A	19.73	19.73
ORIC Oric Pharmaceuticals	N/A	13.19	13.19
REPL Replimune Group	1.00	5.23	5.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTC Benitec Biopharma	52.19%
DMRA Damora Therapeutics, Inc. Common Stock	14.20%
ORIC Oric Pharmaceuticals	95.05%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
BNTC Benitec Biopharma	4.80%
DMRA Damora Therapeutics, Inc. Common Stock	0.40%
ORIC Oric Pharmaceuticals	5.70%
REPL Replimune Group	5.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTC Benitec Biopharma	24	34.88 million	33.21 million	No Data
DMRA Damora Therapeutics, Inc. Common Stock	40	61.74 million	61.49 million	No Data
ORIC Oric Pharmaceuticals	111	103.65 million	97.75 million	Optionable
REPL Replimune Group	465	93.80 million	88.73 million	Optionable

BNTC, DMRA, REPL, and ORIC Headlines

Recent News About These Companies

Replimune Group (NASDAQ:REPL) Stock Falls 6.7% - What's Next?

October 13 at 3:39 PM | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Stock Has Consensus Target Price of $12.00

October 13 at 4:15 AM | americanbankingnews.com

Replimune Group, Inc. (NASDAQ:REPL) Stock Has Consensus Price Target of $12.00 According to Brokerages

October 13 at 4:13 AM | marketbeat.com

Replimune Group (REPL) Launches TUDRIQEV As Its Valuation Story Comes Into Focus

October 9, 2026 | finance.yahoo.com

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

October 5, 2026 | globenewswire.com

Replimune Group, Inc. Announces Tudriqev? Now Commercially Available in the United States for Advanced Melanoma

October 2, 2026 | marketscreener.comM

REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5th

October 2, 2026 | globenewswire.com

Replimune's TUDRIQEV now available in U.S. for advanced melanoma

October 1, 2026 | streetinsider.com

Replimune Receives Approval to Launch Tudriqev in the US for Melanoma

October 1, 2026 | marketscreener.comM

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

October 1, 2026 | globenewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

October 1, 2026 | globenewswire.com

SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL

October 1, 2026 | prnewswire.com

REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky

September 30, 2026 | prnewswire.com

Bank of America Corp DE Purchases New Holdings in Replimune Group, Inc. $REPL

September 30, 2026 | marketbeat.com

REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5th

September 29, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

September 29, 2026 | globenewswire.com

Replimune Group (NASDAQ:REPL) Shares Up 5.1% - Should You Buy?

September 29, 2026 | marketbeat.com

REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class Action - Contact SueWallSt

September 29, 2026 | globenewswire.com

Portnoy Law Firm Announces Class Action on Behalf of Replimune Group, Inc. Investors

September 29, 2026 | globenewswire.com

Robbins LLP is Investigating Allegations that Replimune Group, Inc. Misled Investors Regarding the Efficacy and Viability of its Lead Product Candidate RP1

September 28, 2026 | newsfilecorp.comN

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

September 28, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTC, DMRA, REPL, and ORIC Company Descriptions

Benitec Biopharma NASDAQ:BNTC

$8.45 +0.16 (+1.98%)

As of 04:00 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

$18.74 +0.31 (+1.68%)

As of 04:00 PM Eastern

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Oric Pharmaceuticals NASDAQ:ORIC

$12.77 +1.18 (+10.18%)

Closing price 04:00 PM Eastern

Extended Trading

$12.40 -0.37 (-2.93%)

As of 05:58 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Replimune Group NASDAQ:REPL

$11.75 +0.36 (+3.16%)

Closing price 04:00 PM Eastern

Extended Trading

$11.80 +0.05 (+0.42%)

As of 05:21 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNTC, DMRA, REPL, and ORIC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNTC, DMRA, REPL, and ORIC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNTC, DMRA, REPL, and ORIC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTC, DMRA, REPL, and ORIC Company Descriptions

Benitec Biopharma NASDAQ:BNTC

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

Oric Pharmaceuticals NASDAQ:ORIC

Replimune Group NASDAQ:REPL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNTC, DMRA, REPL, and ORIC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNTC, DMRA, REPL, and ORIC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNTC, DMRA, REPL, and ORIC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTC, DMRA, REPL, and ORIC Company Descriptions

Benitec Biopharma NASDAQ:BNTC

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

Oric Pharmaceuticals NASDAQ:ORIC

Replimune Group NASDAQ:REPL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools